- Home
- XOMA vs DCTH Comparison
XOMA vs DCTH Comparison
Compare XOMA & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMA
- DCTH
- Stock Information
- Founded
- XOMA 1981
- DCTH 1988
- Country
- XOMA United States
- DCTH United States
- Employees
- XOMA N/A
- DCTH N/A
- Industry
- XOMA Biotechnology: Pharmaceutical Preparations
- DCTH Medical/Dental Instruments
- Sector
- XOMA Health Care
- DCTH Health Care
- Exchange
- XOMA Nasdaq
- DCTH Nasdaq
- Market Cap
- XOMA 355.6M
- DCTH 398.2M
- IPO Year
- XOMA N/A
- DCTH N/A
- Fundamental
- Price
- XOMA $26.76
- DCTH $14.31
- Analyst Decision
- XOMA Strong Buy
- DCTH Strong Buy
- Analyst Count
- XOMA 2
- DCTH 4
- Target Price
- XOMA $81.50
- DCTH $22.25
- AVG Volume (30 Days)
- XOMA 36.4K
- DCTH 411.6K
- Earning Date
- XOMA 03-07-2025
- DCTH 11-08-2024
- Dividend Yield
- XOMA N/A
- DCTH N/A
- EPS Growth
- XOMA N/A
- DCTH N/A
- EPS
- XOMA N/A
- DCTH N/A
- Revenue
- XOMA $21,606,000.00
- DCTH $22,644,000.00
- Revenue This Year
- XOMA $511.48
- DCTH $1,605.13
- Revenue Next Year
- XOMA $26.91
- DCTH $111.67
- P/E Ratio
- XOMA N/A
- DCTH N/A
- Revenue Growth
- XOMA 389.82
- DCTH 945.91
- 52 Week Low
- XOMA $18.57
- DCTH $3.70
- 52 Week High
- XOMA $35.00
- DCTH $14.47
- Technical
- Relative Strength Index (RSI)
- XOMA 47.49
- DCTH 70.27
- Support Level
- XOMA $23.88
- DCTH $12.14
- Resistance Level
- XOMA $29.02
- DCTH $12.98
- Average True Range (ATR)
- XOMA 1.27
- DCTH 0.77
- MACD
- XOMA 0.27
- DCTH 0.16
- Stochastic Oscillator
- XOMA 56.03
- DCTH 95.12
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.